Made in Russia

All regions
ENG
Company News

The Skolkovo Foundation reaches an agreement on a strategic partnership in bioinformatics in Cuba

45

Four memorandums of understanding in pharmaceuticals, bioinformatics, genetic data exchange and the creation of start-ups on the basis of the Skolkovo Foundation were signed in Havana, reported the press service of the Fund.

President of the Skolkovo Viktor Vekselberg called the signing of the agreement on strategic partnership in innovation between companies of the Foundation and the Center for Genetic Engineering and Biotechnology of Cuba, "quite an extraordinary event."

The project participants have become pharmaceutical company "R-Pharm", scientific and pharmaceutical center ChemRar, the First Oncology Research and Advisory Center (FORAC) and the Institute of Human Stem Cells.

Russian-Cuban relations have historically always been above board, warm and mutually beneficial, but today they acquire a new character, today an agreement was signed in a completely different area; in the field of innovation in the biomedical field," Vekselberg commented on the event. He noted that "today we turn another page in mutual cooperation, in cultivation of joint projects and in the development of Russian, Cuban and Latin American markets. Cuba has a long history of successful work in the field of medicine and if we are able to excert our joint efforts in this area, I believe that we will achieve a new standard of quality".

In the framework of agreements with Russian companies, the transfer of Cuban projects in the form of Skolkovo startup participants is being considered.

The head of the company Heber Biotec, Eulogio Pimentel declared that agreements with Skolkovo will mark a "turning point in the Cuban biotechnology field," quotes the Prensa Latina agency.

"Russia is one of the top priority markets for our products," noted Eulogio Pimentel in an interview with the Granma gazette. "Heber Biotec has already registered a number of products in Russia and is carrying out clinical tests in various Russian regions, while launching pilot projects; but there is still a lot of work ahead."

The director of the Center for Genetic Engineering and Biotechnology of Cuba, Eulogio Pimentel, signed from the Cuban side. From the Russian side, the document was signed by the deputy CEO of R-PHARM, Dmitriy Sholobov; the chairman of the board of directors of the scientific, pharmaceutical centre ChemRar, Nikolay Savchuk; director of strategic partnerships at The First Oncology Research and Advisory Centre; President of the Institute of Human Stem Cell, Artur Isayev and Vice-President of the Skolkovo Foundation; the acting director of the cluster of biomedical technologies, Kirill Kay.

0